GTx, Inc. (NASDAQ: GTXI)

GTx, Inc. (NASDAQ: GTXI) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions. The company’s product candidate in clinical development, ACAPODENE, is a selective estrogen receptor modulator that is in pivotal Phase III clinical trials for the treatment of multiple serious side effects of androgen deprivation therapy for advanced prostate cancer. For further information, visit the Company’s web site at www.gtxinc.com.